Page last updated: 2024-11-02

pioglitazone and Critical Illness

pioglitazone has been researched along with Critical Illness in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Critical Illness: A disease or state in which death is possible or imminent.

Research Excerpts

ExcerptRelevanceReference
" Pioglitazone was associated with increased peripheral insulin sensitivity (+23%-72%, standardized mean difference of 0."9.41Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review. ( Davies, TW; Fowler, AJ; McClelland, TJ; Pearse, R; Prowle, J; Puthucheary, Z, 2023)
" Pioglitazone was associated with increased peripheral insulin sensitivity (+23%-72%, standardized mean difference of 0."5.41Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review. ( Davies, TW; Fowler, AJ; McClelland, TJ; Pearse, R; Prowle, J; Puthucheary, Z, 2023)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
McClelland, TJ1
Fowler, AJ1
Davies, TW1
Pearse, R1
Prowle, J1
Puthucheary, Z1
Kaplan, JM1
Zingarelli, B1
Krallman, K1
Tang Girdwood, S1
Lagory, D1
Mizuno, T1
Fei, L1
Wong, HR1
Vinks, AA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock[NCT01352182]Phase 1/Phase 212 participants (Actual)Interventional2011-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Effect of Pioglitazone Area Under the Curve on Changes in IL-6

We examined the effect of pioglitazone Area under the curve on IL-6 in patients receiving pioglitazone only. (Control subjects did not receive pioglitazone). The pharmacokinetic endpoint was area under the curve (AUC) total/days of pioglitazone administration (NCT01352182)
Timeframe: Evaluation of inflammatory biomarkers will be obtained prior to dosing for the first five days of the study

Interventionng/ml (Least Squares Mean)
Pioglitazone Hydrochloride-1.4425
Normal Standard CareNA

Evaluate the Safety Profile of Pioglitazone in Patients With Severe Sepsis and Septic Shock as the Number of Hypoglycemic Events

The number of hypoglycemic events in pioglitazone vs standard care. Hypoglycemia was defined as blood glucose level that remains <40mg/dl despite dextrose bolus treatment. (NCT01352182)
Timeframe: Assessement over five days

Interventionevents (Number)
Pioglitazone Hydrochloride0
Normal Standard Care0

Pioglitazone Area Under Curve Estimates by Treatment Group and Route of Administration

Pioglitazone concentration as the total area under curve divided by the number of days receiving the drug in subjects who took the drug by mouth versus by naso-gastric tube (NCT01352182)
Timeframe: five days

Interventionng*h/ml (Mean)
Pioglitazone Hydrochloride by Mouth5363
Pioglitazone Hydrochloride by Nasogastric Tube1052

Safety Labs - Alanine Aminotransferase (ALT)

ALT levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study

InterventionU/L (Median)
Pioglitazone Hydrochloride21.5
Normal Standard Care24.5

Safety Labs - Blood Urea Nitrogen (BUN)

BUN levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study

Interventionmg/dl (Median)
Pioglitazone Hydrochloride7.5
Normal Standard Care10

Safety Labs - Creatinine

Creatinine levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study

Interventionmg/dl (Median)
Pioglitazone Hydrochloride0.72
Normal Standard Care0.415

Reviews

1 review available for pioglitazone and Critical Illness

ArticleYear
Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review.
    JPEN. Journal of parenteral and enteral nutrition, 2023, Volume: 47, Issue:4

    Topics: Adult; Critical Illness; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone

2023

Trials

1 trial available for pioglitazone and Critical Illness

ArticleYear
Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial.
    Intensive care medicine, 2018, Volume: 44, Issue:11

    Topics: Critical Illness; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Sepsis

2018